(Q41467631)

1 October 2017

title

Treatment of reactive arthritis with infliximab (English)

1 reference

1 October 2017

1 reference

Kaipiainen-Seppänen Oili

1

1 reference

1 October 2017

Helena Niinisalo

2

1 reference

1 October 2017

Tuula Korpilähde

3

1 reference

1 October 2017

Jukka Virolainen

4

1 reference

1 October 2017

publication date

1 January 2003

1 reference

Scandinavian Journal of Rheumatology

1 October 2017

published in

1 reference

1 October 2017

volume

32

1 reference

1 October 2017

issue

2

1 reference

1 October 2017

page(s)

122-124

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

Reiter's Syndrome and Reactive Arthritis in Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

Ten-year follow-up study of patients with Yersinia arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

Therapeutic aspects of spondyloarthropathies -- a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740310000157

10.1080/03009740310000157

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference